Results 171 to 180 of about 407,552 (296)

Intravenous immunoglobulin frequency in multifocal motor neuropathy: a retrospective study of nerve conduction outcomes. [PDF]

BMC Neurol
Zhou L, He Z, Fang W, Yang H, Sheng X, Meng Y, Zhu X, Wang R, Wang H.   +8 more
europepmc   +1 more source

IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay, Alexia Orellana, George C. Tsokos, Rhea Bhargava   +3 more
wiley   +1 more source

Study on intravenous immunoglobulin use in a pediatric intensive care unit of a tertiary care center. [PDF]

World J Clin Pediatr
Varadarajan P, Subramani S, Jeyaram V, Velmurugan LS, Jayaseelan R, Venugopal GS.   +5 more
europepmc   +1 more source

Dnmt3a Mutations Limit Normal and Autoreactive CD4+ T Follicular Helper Responses and Attenuate T Cell–Driven Joint Inflammation

Arthritis &Rheumatology, EarlyView.
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen, Sanjaykumar Boddul, Zhaojun Li, Zsolt Kasza, Marlene Schülein, Bruno Raposo, Karine Chemin, Per‐Johan Jakobsson, Alexander Espinosa, Lars Klareskog, Fredrik Wermeling   +10 more
wiley   +1 more source

Dermato-Neuro Syndrome After Intravenous Immunoglobulin Infusion: Case Report. [PDF]

Reports (MDPI)
Kassalow B, Kazmi S, Shukri S, London ZN.   +3 more
europepmc   +1 more source

CD248/Endosialin Regulates Synovial Fibroblast State to Control Coupling of Inflammation and Bone Damage in Murine Models of Immune‐Mediated Inflammatory Arthritis and Aging

Arthritis &Rheumatology, EarlyView.
Objective Synovial fibroblasts directly contribute to inflammation and damage in immune‐mediated inflammatory arthritis. CD248/endosialin is expressed by fibroblasts in the synovium, is highly up‐regulated during inflammation, and has been proposed as a potential therapeutic target.
Samuel Kemble, Corinna Wehmeyer, James M. Brown, Charlotte G. Smith, Holly R. Adams, Eva Crombie, Ellie Northall, Maryam Imran, Paulynn Chin, Harris R. Perlman, Christopher D. Buckley, Adam P. Croft, Amy J. Naylor   +12 more
wiley   +1 more source

Association between sodium content of intravenous immunoglobulin and electrolyte changes and clinical course of Kawasaki disease. [PDF]

Clin Exp Pediatr
Watanabe Y, Yagi N, Hattori T, Oyake C, Endo S, Endo S, Yoshimi M, Kyoda T, Ikeda H.   +8 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Case Report: Balancing immunosuppression and infection-intravenous immunoglobulin in anti-HMGCR immune-mediated necrotizing myopathy complicated by severe pneumonia. [PDF]

Front Med (Lausanne)
Fu J, Zhao Q, Lou JB, Tang GH, Chen W, Zhao JH, He QS.   +6 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source